EGFR and non-small cell lung carcinoma: These aspects are not only critical for improving current targeted therapy approaches, but also provide important and clinically relevant information for future investigations on combining immunotherapy with TKIs to further stimulate and improve the antitumour immune response in EGFR-driven NSCLC.